Advertisement
Screener

ProPhase Labs, Inc. (PRPH) Amortization of Debt Discount (Premium)

2.8 / 5 stars · 68/120 Roast Me

ProPhase Labs, Inc. Amortization of Debt Discount (Premium)

ProPhase Labs, Inc. (PRPH) reported Amortization of Debt Discount (Premium) of $5.24 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.

Financial Statements › Cash Flow › Operating Activities

us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-06-01

  • ProPhase Labs, Inc. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $3.42M, a 581.87% increase year-over-year.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $964.00K, a 57.00% increase year-over-year.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $477.00K, a 108.30% increase year-over-year.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $372.00K, a 165.71% increase year-over-year.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for fiscal 2025 was $5.24M, a 252.59% increase from fiscal 2024.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for fiscal 2024 was $1.49M, a 1025.00% increase from fiscal 2023.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for fiscal 2023 was $132.00K, a 3200.00% increase from fiscal 2022.
  • ProPhase Labs, Inc. amortization of debt discount (premium) for fiscal 2022 was $4.00K, a 20.00% decline from fiscal 2021.
Period endAmortization of Debt Discount (Premium) 3 monthAmortization of Debt Discount (Premium) 3 month as first filedAmortization of Debt Discount (Premium) 6 monthAmortization of Debt Discount (Premium) 6 month as first filedAmortization of Debt Discount (Premium) 9 monthAmortization of Debt Discount (Premium) 9 month as first filedAmortization of Debt Discount (Premium) 12 month
2025-12-31$3.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01
$4.39M
derived: sum of 2 quarters · filed 2026-06-01
$4.86M
derived: sum of 3 quarters · filed 2026-06-01
$5.24M
10-K · filed 2026-06-01
2025-09-30$964.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$1.44M
derived: sum of 2 quarters · filed 2025-11-19
$1.81M
10-Q · filed 2025-11-19
$2.31M
derived: sum of 4 quarters · filed 2026-06-01
2025-06-30$477.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$849.00K
10-Q · filed 2025-08-13
$1.35M
derived: sum of 3 quarters · filed 2026-06-01
$1.97M
derived: sum of 4 quarters · filed 2026-06-01
2025-03-31$372.00K
10-Q · filed 2025-05-20
$874.00K
derived: sum of 2 quarters · filed 2026-06-01
$1.49M
derived: sum of 3 quarters · filed 2026-06-01
$1.72M
derived: sum of 4 quarters · filed 2026-06-01
2024-12-31$502.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01
$1.12M
derived: sum of 2 quarters · filed 2026-06-01
$1.34M
derived: sum of 3 quarters · filed 2026-06-01
$1.49M
10-K · filed 2026-06-01
2024-09-30$614.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$843.00K
derived: sum of 2 quarters · filed 2025-11-19
$983.00K
10-Q · filed 2025-11-19
$1.00M
10-Q · filed 2024-11-13
$1.02M
derived: sum of 4 quarters · filed 2025-11-19
2024-06-30$229.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$369.00K
10-Q · filed 2025-08-13
$381.00K
10-Q · filed 2024-08-14
$404.00K
derived: sum of 3 quarters · filed 2025-08-13
$457.00K
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$140.00K
10-Q · filed 2025-05-20
$146.00K
10-Q · filed 2024-05-10
$175.00K
derived: sum of 2 quarters · filed 2025-05-20
$228.00K
derived: sum of 3 quarters · filed 2025-05-20
$252.00K
derived: sum of 4 quarters · filed 2025-05-20
2023-12-31$35.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01
$88.00K
derived: sum of 2 quarters · filed 2025-04-01
$112.00K
derived: sum of 3 quarters · filed 2025-04-01
$132.00K
10-K · filed 2025-04-01
2023-09-30$53.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$77.00K
derived: sum of 2 quarters · filed 2024-11-13
$97.00K
10-Q · filed 2024-11-13
$97.00K
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$24.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$44.00K
10-Q · filed 2024-08-14
$44.00K
derived: sum of 3 quarters · filed 2024-08-14
$46.00K
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$20.00K
10-Q · filed 2024-05-10
$20.00K
derived: sum of 2 quarters · filed 2024-05-10
$22.00K
derived: sum of 3 quarters · filed 2024-05-10
$23.00K
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$2.00K
derived: sum of 2 quarters · filed 2024-03-29
$3.00K
derived: sum of 3 quarters · filed 2024-03-29
$4.00K
10-K · filed 2024-03-29
2022-09-30$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$3.00K
derived: sum of 2 quarters · filed 2023-11-13
$4.00K
10-Q · filed 2023-11-13
$5.00K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$2.00K
10-Q · filed 2023-08-11
$3.00K
derived: sum of 3 quarters · filed 2023-08-11
$4.00K
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31$1.00K
10-Q · filed 2023-05-12
$2.00K
derived: sum of 2 quarters · filed 2023-05-12
$3.00K
derived: sum of 3 quarters · filed 2023-05-12
$4.00K
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
$2.00K
derived: sum of 2 quarters · filed 2023-03-29
$3.00K
derived: sum of 3 quarters · filed 2023-03-29
$5.00K
10-K · filed 2023-03-29
2021-09-30$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$2.00K
derived: sum of 2 quarters · filed 2022-11-10
$4.00K
10-Q · filed 2022-11-10
2021-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
$3.00K
10-Q · filed 2022-08-12
2021-03-31$2.00K
10-Q · filed 2022-05-13
2020-12-31$1.00K
10-K · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Pulmatrix, Inc. (PULM)United States$0.006B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26